drugset / Trial / NCT01328834

Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis

NCT01328834

Phase 3 Completed 20 enrolled Sun Yat-sen University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment for the induction therapy of refractory lupus nephritis (LN).

Timeline

Start
2011-01
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.05 mg/kg
Subject Tacrolimus Small molecule 0.1 mg/kg

Indications